[1]唐 剑.联用参麦注射液与左卡尼汀治疗血液透析期间低血压的效果及对血流动力学的影响[J].医学信息,2023,36(21):142-145.[doi:10.3969/j.issn.1006-1959.2023.21.033]
　TANG Jian.Effect of Shenmai Injection Combined with Levocarnitine in the Treatment of Hypotension During Hemodialysis and its Influence on Hemodynamics[J].Journal of Medical Information,2023,36(21):142-145.[doi:10.3969/j.issn.1006-1959.2023.21.033]
点击复制

联用参麦注射液与左卡尼汀治疗血液透析期间低血压的效果及对血流动力学的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年21期
页码:
142-145
栏目:
药物与临床
出版日期:
2023-11-01

文章信息/Info

Title:
Effect of Shenmai Injection Combined with Levocarnitine in the Treatment of Hypotension During Hemodialysis and its Influence on Hemodynamics
文章编号:
1006-1959（2023）21-0142-04
作者:
唐 剑
（江西医学高等专科学校第一附属医院肾内科，江西 上饶 334000）
Author(s):
TANG Jian
(Department of Nephrology,the First Affiliated Hospital of Jiangxi Medical College,Shangrao 334000,Jiangxi,China)
关键词:
血液透析; 血液透析相关性低血压; 左卡尼汀; 参麦注射液; 血流动力学
Keywords:
Hemodialysis; Intradialytic-hypotension; Levocarnitine; Shenmai injection; Hemodynamics
分类号:
R692.5
DOI:
10.3969/j.issn.1006-1959.2023.21.033
文献标志码:
A
摘要:
目的 研究联用参麦注射液与左卡尼汀治疗血液透析期间低血压的效果及对血流动力学的影响。方法 以2020年7月-2022年7月于江西医学高等专科学校第一附属医院行血液透析治疗的80例血液透析相关性低血压（IDH）患者为研究对象，按照随机数字表法分为对照组（40例）与观察组（40例），对照组给予左卡尼汀治疗，观察组在其基础上联用参麦注射液治疗。比较两组临床疗效、血压水平[收缩压（SBP）、舒张压（DBP）]、血流动力学指标[平均动脉压（MAP)、心率（HR）]、血透相关指标[尿素清除指数（KT/V）、超滤量]。结果 观察组总有效率高于对照组（P＜0.05）；两组透析中SBP、DBP水平均低于透析前，两组透析后SBP、DBP水平均高于透析中（P＜0.05），且观察组透析中及透析后SBP、DBP水平均高于对照组（P＜0.05）。对照组透析后MAP低于透析前，HR高于透析前（P＜0.05），观察组透析前后MAP、HR比较，差异无统计学意义（P＞0.05），且两组透析后MAP、HR比较，差异有统计学意义（P＜0.05）。观察组KT/V值、超滤量均大于对照组（P＜0.05）。结论 参麦注射液联合左卡尼汀治疗血透期间低血压疗效突出，可减少血压波动，改善患者血流动力稳定性，提高透析充分性，值得临床应用。
Abstract:
Objective To study the effect of Shenmai injection combined with levocarnitine in the treatment of hypotension during hemodialysis and its influence on hemodynamics.Methods A total of 80 patients with intradialytic-hypotension (IDH) who underwent hemodialysis in the First Affiliated Hospital of Jiangxi Medical College from July 2020 to July 2022 were selected as the research objects. According to the random number table method, they were divided into control group (40 patients) and observation group (40 patients). The control group was treated with levocarnitine, and the observation group was treated with Shenmai injection on the basis of levocarnitine treatment. The clinical efficacy, blood pressure level [systolic blood pressure (SBP), diastolic blood pressure (DBP)], hemodynamic indexes [mean arterial pressure (MAP), heart rate (HR)], hemodialysis related indexes [urea clearance index (KT/V), ultrafiltration volume] were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group (P<0.05). The levels of SBP and DBP during dialysis in the two groups were lower than those before dialysis, and the levels of SBP and DBP after dialysis in the two groups were higher than those during dialysis (P<0.05), and the levels of SBP and DBP during and after dialysis in the observation group were higher than those in the control group (P<0.05). After dialysis, MAP in the control group was lower than that before dialysis, and HR was higher than that before dialysis (P<0.05). There was no significant difference in MAP and HR before and after dialysis in the observation group (P>0.05), and there were significant differences in MAP and HR between the two groups after dialysis (P<0.05). The KT/V value and ultrafiltration volume of the observation group were higher than those of the control group (P<0.05).Conclusion Shenmai injection combined with levocarnitine is effective in the treatment of hypotension during hemodialysis, which can reduce blood pressure fluctuation, improve hemodynamic stability and dialysis adequacy, it is worthy of clinical application.

参考文献/References:

[1]陈奕鸣,陈静,尹忠诚.维持血液透析病人并发低血压的临床特征分析[J].蚌埠医学院学报,2022,47(3):313-316.[2]郭立华,倪梓元,辛光大.低血压对血液透析患者远期生存状况的影响[J].检验医学与临床,2017,14(22):3343-3345.[3]潘璐璐,何颖雪,邵国建.维持性血液透析患者发生透析中低血压的相关危险因素分析[J].浙江医学,2019,41(22):2421-2423,2437.[4]Miskulin DC,Weiner DE.Blood Pressure Management in Hemodialysis Patients: What We Know And What Questions Remain[J].Seminars in Dialysis,2017,30(3):203-212.[5]潘月娟,卢方平.大剂量左卡尼汀在不能耐受血液透析的尿毒症合并心脏病患者中的应用[J].中华医学杂志,2017,97(48):3792-3795.[6]徐海平,李秀丽,孙立娜,等.左卡尼汀对维持性血液透析患者炎症因子、氧化应激指标及心脏功能的影响[J].中国药房,2017,28(11):1558-1561.[7]李迎婕,魏晓岩,贾军利,等.左卡尼汀对维持性血液透析终末期肾病患者营养状况及心功能的影响研究[J].临床误诊误治,2019,32(10):38-41.[8]林玲,彭梅,罗凯,等.参麦注射液对血液透析相关性低血压患者血压、血清白蛋白及透析充分性的影响[J].河北中医,2019,41(5):706-709.[9]中国医药教育协会肾病与血液净化专业委员会血液透析低血压防治专家组.血液透析中低血压防治专家共识(2022)[J].中华内科杂志,2022,61(3):269-281.[10]Keane DF,Raimann JG,Zhang H,et al.The time of onset of intradialytic hypotension during a hemodialysis session associates with clinical parameters and mortality[J].Kidney International,2021,99(6):1408-1417.[11]李梦甜,庄冰,陈静,等.维持性血液透析患者透析中低血压与人体成分的关系[J].现代生物医学进展,2021,21(11):2053-2056.[12]唐丽娟,胡俊,张婧.左卡尼汀联合生脉注射液对维持性血液透析患者心血管系统的影响[J].皖南医学院学报,2019,38(6):538-542.[13]徐海平,张浩然,马晓迎,等.左卡尼汀在维持性血液透析和维持性腹膜透析患者中药代动力学特点[J].中国医药导刊,2017,19(5):494-496.[14]杨雪莲,马云伶,许娜,等.左卡尼丁对维持性血液透析患者低血压和肌肉痉挛的疗效观察[J].中国中西医结合肾病杂志,2017,18(3):253-254．[15]肖虹,赵金玲,任文英.血液透析相关性低血压与中医证型分布及症状困扰的相关性研究[J].中国中西医结合肾病杂志,2021,22(8):706-709.[16]江巧梨,许帅,邹洪斌.生脉饮联合参类治疗中老年血液透析相关性低血压[J].长春中医药大学学报,2018,34(1):114-115.[17]许绍芳.参麦注射液对血液透析相关性低血压防治效果观察[J].中医临床研究,2017,9(10):103-104.[18]张晓琴,童海香.帕立骨化醇联合左卡尼汀治疗维持性血液透析继发性甲状旁腺功能亢进的临床研究[J].中国处方药,2022,20(4):130-132[19]彭用华,陈寿明,俞小敏,等.参麦注射液减少透析中低血压的随机对照研究[J].中医药导报,2017,23(20):76-78.[20]曹颖,王春梅,傅强.参麦注射液对感染性休克患者血流动力学及血清炎症因子的影响[J].中国中西医结合急救杂志,2019,26(1):38-40．[21]范立明,黄远航,钟先阳.参麦注射液防治血液透析相关性低血压的临床疗效及对透析充分性的影响[J].河北中医,2018,40(4):531-534.

相似文献/References:

[1]肖一红.组合型人工肾技术预防血液透析中低血压的效果观察[J].医学信息,2018,31(03):185.[doi:10.3969/j.issn.1006-1959.2018.03.070]
　XIAO Yi-hong.Effect of Combined Artificial Renal Technique in Preventing Hypotension in Hemodialysis[J].Journal of Medical Information,2018,31(21):185.[doi:10.3969/j.issn.1006-1959.2018.03.070]
[2]邹 鑫,刘秀娟,余燕燕.血液透析对MHD患者血清FGF-23水平与 钙磷代谢的影响[J].医学信息,2018,31(09):119.[doi:10.3969/j.issn.1006-1959.2018.09.036]
　ZOU Xin,LIU Xiu-juan,YU Yan-yan.Effect of Hemodialysis on Serum FGF-23 Level and Calcium and Phosphorus Metabolism in MHD Patients[J].Journal of Medical Information,2018,31(21):119.[doi:10.3969/j.issn.1006-1959.2018.09.036]
[3]王允彦.西那卡塞对维持性血液透析继发性甲状旁腺功能亢进患者FGF-23的影响[J].医学信息,2018,31(13):88.[doi:10.3969/j.issn.1006-1959.2018.13.025]
　WANG Yun-yan.Effect of Cinacalcet on FGF-23 in Patients with Secondary Hyperparathyroidism during Maintenance Hemodialysis[J].Journal of Medical Information,2018,31(21):88.[doi:10.3969/j.issn.1006-1959.2018.13.025]
[4]蒋红利,刘 华,史珂慧,等.陕西省县级医院透析室建设项目培训效果评价[J].医学信息,2018,31(19):120.[doi:10.3969/j.issn.1006-1959.2018.19.036]
　JIANG Hong-li,LIU Hua,SHI Ke-hui,et al.Evaluation on Training Effect of Dialysis Room Construction Project in County Hospitals in Shaanxi Province[J].Journal of Medical Information,2018,31(21):120.[doi:10.3969/j.issn.1006-1959.2018.19.036]
[5]方海东,李 荣.血液透析滤过联合血液透析治疗慢性肾功能衰竭的效果观察[J].医学信息,2019,32(02):129.[doi:10.3969/j.issn.1006-1959.2019.02.037]
　FANG Hai-dong,LI Rong.Effect of Hemodiafiltration Combined with Hemodialysis on Chronic Renal Failure[J].Journal of Medical Information,2019,32(21):129.[doi:10.3969/j.issn.1006-1959.2019.02.037]
[6]张民霞.血液灌流联合血液透析治疗肾功能衰竭难治性高血压的效果[J].医学信息,2019,32(15):109.[doi:10.3969/j.issn.1006-1959.2019.15.035]
　ZHANG Min-xia.Effect of Hemoperfusion Combined with Hemodialysis on Refractory Hypertension with Renal Failure[J].Journal of Medical Information,2019,32(21):109.[doi:10.3969/j.issn.1006-1959.2019.15.035]
[7]谢 华,周毅峰,甘晓庆,等.血液透析专用中心静脉导管封管液的研究[J].医学信息,2019,32(18):48.[doi:10.3969/j.issn.1006-1959.2019.18.016]
　XIE Hua,ZHOU Yi-feng,GAN Xiao-qing,et al.Research on Central Venous Catheter Sealing Fluid for Hemodialysis[J].Journal of Medical Information,2019,32(21):48.[doi:10.3969/j.issn.1006-1959.2019.18.016]
[8]喻学娜.协同护理对终末期肾脏病血液透析患者自我护理能力及治疗依从性的影响[J].医学信息,2019,32(20):183.[doi:10.3969/j.issn.1006-1959.2019.20.059]
　YU Xue-na.Effect of Collaborative Nursing on Self-care Ability and Treatment Compliance of Hemodialysis Patients with End-stage Renal Disease[J].Journal of Medical Information,2019,32(21):183.[doi:10.3969/j.issn.1006-1959.2019.20.059]
[9]魏昌林.血液透析联合血液灌流在终末期肾病患者治疗中的应用[J].医学信息,2019,32(13):109.[doi:10.3969/j.issn.1006-1959.2019.13.032]
　WEI Chang-lin.Application of Hemodialysis Combined with Blood Perfusion in the Treatment of Patients with End-stage Renal Disease[J].Journal of Medical Information,2019,32(21):109.[doi:10.3969/j.issn.1006-1959.2019.13.032]
[10]钟瑜辉.血液透析联合血液灌流治疗尿毒症的效果[J].医学信息,2019,32(21):108.[doi:10.3969/j.issn.1006-1959.2019.21.034]
　ZHONG Yu-hui.Effect of Hemodialysis Combined with Blood Perfusion on Uremia[J].Journal of Medical Information,2019,32(21):108.[doi:10.3969/j.issn.1006-1959.2019.21.034]

更新日期/Last Update: 1900-01-01